Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R-2-CHOP in subjects with previously untreated, high-risk DLBCL.

Nowakowski, GS; Willenbacher, W; Greil, R; Larsen, TS; Patel, K; Jager, U; Manges, RF; Trumper, LH; Haioun, C; Everaus, H; Kalakonda, N; Knoble, J; Brown, P; Joergensen, JM; Cunningham, D; Domper, N; Casadebaig, ML; Manzke, O; Munoz, J

View this publication in the PUBMED database